Your session is about to expire
← Back to Search
Dostarlimab + Chemotherapy for Endometrial Cancer (RUBY Trial)
RUBY Trial Summary
This trial is testing a new immunotherapy drug combo against placebo to see if it's more effective in treating endometrial cancer.
RUBY Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRUBY Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RUBY Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My endometrial cancer has come back more than once.My endometrial cancer is advanced and not likely cured by surgery or radiation alone.I have a serious heart condition.I can take medication by mouth.I have a higher risk of bleeding due to other health conditions.My cancer has returned for the first time and I haven't had any cancer drugs yet.I have untreated brain metastases or carcinomatous meningitis.I have recovered from previous cancer treatment side effects and haven't had blood transfusions or certain medications in the last 3 weeks.I have a serious health condition that is not under control.My blood pressure is normal or well-controlled under 140/90 mmHg.My cancer returned or worsened within 6 months after finishing my last cancer treatment.I still have side effects from recent major surgery.My cancer is Stage IIIC1 with specific cell types and may not show on scans.I have not had, nor plan to have, a live vaccine around the time of my treatment.I have been treated with a PARP inhibitor before.I have a history or current diagnosis of MDS or AML.I haven't had cancer treatment within the last 21 days or less than 5 half-lives of my last therapy.I am fully active or restricted in physically strenuous activity but can do light work.I have been treated with drugs targeting the PD-1 or PD-L1/L2 pathways.My cancer has not worsened or returned before starting this study.I have another cancer type or was treated for a non-skin cancer in the last 3 years.I have not been in a clinical trial for a new treatment or device within the last 4 weeks.My cancer is at stage IIIC2 or IV.My cancer returned 6 months or more after finishing initial treatment.I had treatment before or after surgery for stage III or IV cancer.My cancer is at stage IIIA to IIIC1 and can be measured or evaluated.I am a woman aged 18 or older.My endometrial cancer has come back or spread and is confirmed by tests.My organs are functioning well.
- Group 1: Arm 4: Participants receiving placebo + carboplatin-paclitaxel followed by placebo
- Group 2: Arm 1: Participants receiving dostarlimab + Carboplatin-paclitaxel followed by dostarlimab
- Group 3: Arm 2: Participants receiving placebo + carboplatin-paclitaxel followed by placebo
- Group 4: Arm 3: Participants receiving dostarlimab + carboplatin-paclitaxel followed by dostarlimab+niraparib
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Arm 1: Participants receiving dostarlimab + Carboplatin-paclitaxel followed by dostarlimab, is this treatment plan FDA approved?
"Arm 1 of this trial, which includes the administration of dostarlimab + Carboplatin-paclitaxel followed by dostarlimab, is estimated to be a 3 on Power's safety scale. This is due to it being a Phase 3 trial, thus having both efficacy and safety data supporting its use."
What types of cancer are patients in Arm 1: Participants receiving dostarlimab + Carboplatin-paclitaxel followed by dostarlimab typically being treated for?
"melanoma patients often receive dostarlimab + Carboplatin-paclitaxel followed by dostarlimab, which has also been shown to ameliorate neoplasm metastasis, lymphoma, non-hodgkin's sarcoma, and advanced forms of sarcoma."
What other research has been conducted with subjects who received dostarlimab in combination with Carboplatin-paclitaxel, followed by more dostarlimab?
"As of now, there are 1,328 ongoing studies for arm 1: dostarlimab + Carboplatin-paclitaxel followed by dostarlimab. Phase 3 trials make up a significant portion with 351 cases. Most trial locations for this arm are based in Shanghai however; there are 69,749 total locations running these kinds of trials."
In how many different locations is this trial being conducted?
"Currently, there are 59 locations worldwide where patients can enroll in this study. Some of these sites include Willow Grove, Sault Ste. Marie and Rio Rancho. To reduce travel-related stressors, it is recommended that you pick the location nearest to you."
To date, how many individuals have signed up for this experiment?
"Currently, this trial is not taking on new patients. The listing was first posted on 18 July 2019 and was edited last on 11 August 2020. However, there are 2713 cancer trials and 1328 Arm 1 trials (dostarlimab + Carboplatin-paclitaxel followed by dostarlimab) that are still recruiting patients."
Is there still room for participants in this research?
"2713 cancer trials and 1328 Arm 1 studies are currently looking for participants, but this particular clinical trial is not presently searching for candidates. This study was posted on July 18th, 2019 and last updated on August 11th, 2022."
Share this study with friends
Copy Link
Messenger